Stay Pending IPR

When a patent defendant files a petition for inter partes review (IPR) with the PTAB, they often also file a motion to stay the parallel district court patent infringement litigation pending the outcome of the IPR proceeding. WHY DEFENDANTS SEEK STAYS: (1) EFFICIENCY: if the PTAB cancels the asserted claims, the entire district court case goes away without the expense of full litigation; (2) SIMPLIFICATION: even a partial IPR that cancels some claims simplifies the district court case; if the PTAB construes the surviving claims, that guidance can inform district court proceedings; (3) COST SAVINGS: IPR costs $300–800K per side; district court litigation costs $3–5M+ per side; staying the district court case during IPR avoids wasted litigation expense; (4) FINTIV INTERACTION: the threat of a district court stay also affects the PTAB's Fintiv discretionary denial analysis — if the district court is likely to grant a stay (Fintiv Factor 3), the PTAB is less likely to deny institution; WHY PLAINTIFFS OPPOSE STAYS: (1) DELAY: plaintiffs have strong interest in timely relief; a stay can add 18–24 months before trial; (2) UNCERTAINTY: PTAB may not institute; even if instituted, some claims may survive; (3) COMPETITIVE HARM: continuing infringement during the stay causes ongoing harm (especially if preliminary injunction was denied); (4) ESTOPPEL LOSS: if the defendant's IPR results in estoppel, that's a benefit for the plaintiff — but only if the IPR moves forward.

No statute requires district courts to stay cases pending IPR. Courts have discretion, and most circuits apply a version of the standard three-factor test: (1) WHETHER THE LITIGATION IS AT AN EARLY STAGE: courts are more likely to grant stays early in litigation (before or shortly after contentions, before substantial discovery); once a Markman order has issued, claim construction is complete, and significant resources have been invested, courts are less willing to stay the case; courts often note whether trial is imminent; (2) WHETHER A STAY WILL SIMPLIFY THE ISSUES: the key question is whether the IPR, if instituted, is likely to resolve or simplify the case; if the defendant challenges all asserted claims in the IPR on § 102/103 grounds, a successful IPR would eliminate the case entirely; partial challenges create partial simplification; § 101 and § 112 grounds cannot be raised in IPR (reserved for district court) — so even a fully successful IPR might leave some invalidity defenses intact; (3) WHETHER A STAY WOULD UNDULY PREJUDICE THE PLAINTIFF: courts consider whether the patent owner would suffer undue prejudice or a clear tactical disadvantage; factors: (a) the parties are direct competitors (ongoing infringement causes marketplace harm); (b) the plaintiff has been denied a preliminary injunction and infringement continues; (c) the plaintiff's only remedy is past damages (no ongoing harm because defendant has stopped or modified its product); (d) the monetary damages will be adequate to compensate for delay; RELATIVE WEIGHT: courts apply the three factors holistically; no single factor is determinative; statistical studies suggest stays are granted roughly 50–60% of the time after IPR institution, less often pre-institution.

Apple v. Fintiv (PTAB 2020, designated precedential) is a PTAB framework for discretionary denial of IPR institution based on the parallel district court proceeding — it is the PTAB analog to the district court's stay analysis, and the two are closely interrelated: FINTIV SIX FACTORS: (1) whether the court has granted or is likely to grant a stay; (2) proximity of the trial date (or scheduled trial date); (3) investment by the PTAB and parties to date; (4) overlap between the IPR and district court case; (5) whether the petitioner and defendant in the district court are the same party; (6) other circumstances that impact the efficiency or merit of institution; INTERACTION WITH STAY MOTIONS: Factor 1 (likelihood of stay) — if the district court grants a stay, Fintiv weighs heavily in favor of institution; courts and litigants recognize that a granted stay makes it likely the PTAB will institute; Factor 2 (trial date proximity) — a late trial date (18+ months away) supports institution; an imminent trial (within 6 months) may lead to discretionary denial; STRATEGIC SEQUENCING: file the IPR petition first, then move for a stay in district court; use the IPR petition as evidence of substantive invalidity arguments in the stay motion; in the stay motion, emphasize that the IPR will simplify the case and the trial date is sufficiently distant; 2022 DIRECTOR REVIEW CHANGES: in 2022, USPTO Director Vidal issued guidance narrowing Fintiv — IPR petitions that show compelling unpatentability evidence should be instituted even if Fintiv factors counsel otherwise; Sotera Stipulation (defendant stipulates to not asserting in district court the same grounds raised in IPR) also mitigates Fintiv concerns.

Statistical data on stay grants shows significant variation by venue and timing: OVERALL STATISTICS: before IPR institution: courts grant stays approximately 30–45% of the time when the IPR has not yet been instituted; the lower rate reflects that the IPR may not be instituted, making the stay speculative; after IPR institution: courts grant stays approximately 60–70% of the time once the PTAB institutes review; institution signals that at least one claim has a reasonable likelihood of being invalidated; VENUE VARIATION: District of Delaware (the most common patent venue): historically more willing to grant stays; courts there recognize IPR as an efficient alternative; Western District of Texas (WDTX): historically less likely to grant stays; WDTX has moved quickly to trial (often 12–18 months) making stays more disruptive to the court's docket; Eastern District of Texas: similar to WDTX; Northern District of California (NDCA): varies by judge; generally willing to grant stays if the case is not trial-ready; STAGE MATTERS MOST: pre-Markman stays: most commonly granted (50–70%); post-Markman, pre-trial: less common (30–50%); imminent trial (within 6 months): rarely granted; PLAINTIFF STATUS: direct competitors with ongoing marketplace harm are the strongest argument against a stay; non-practicing entities (NPEs/PAEs) have weaker undue prejudice arguments because they lack a product to compete.

FILING TIMING — CRITICAL: file the IPR petition as early as possible within the § 315(b) one-year window; the earlier the IPR petition, the earlier the motion to stay can be filed, and the less litigation investment the district court will need to protect; MOTION TIMING: file the stay motion shortly after filing the IPR petition — don't wait for institution; many courts consider the stay motion on the papers with briefing at the time of the IPR filing; STATUS OF PROCEEDINGS AT IPR FILING: identify the current stage of the case; if contentions have not yet been served, or if Markman has not yet occurred, emphasize the early stage; if the case is advanced, argue the issues are the same and a stay still provides efficiency gains; STREAMLINE ISSUES: demonstrate that the IPR challenges all asserted claims (or the key independent claims that control the case); if partial challenge, explain how cancellation of the challenged claims simplifies or eliminates the district court case; SOTERA STIPULATION: offer to stipulate (in the stay motion or IPR petition) that defendant will not assert the same § 102/103 grounds in district court that are raised in the IPR; this reduces the plaintiff's 'prejudice' from IPR estoppel; addresses one of the Fintiv concerns; WHAT TO AVOID: don't file the stay motion late in the case after substantial investment; don't challenge only peripheral claims while leaving the core asserted claims in district court; PLAINTIFF'S COUNTER-STRATEGY: emphasize direct competitor relationship and ongoing marketplace harm; highlight trial date proximity; argue that IPR cannot address § 101 or § 112 defenses; argue that IPR institution is speculative pre-institution.